Inhaled Corticosteroids on Airway Smooth Muscle in Asthma

• Status: Withdrawn
• Trial end date: 2011-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The main objective is to evaluate how treatment with inhaled corticosteroids (ICS) affects the characteristics of airway smooth muscle (ASM) cells from asthmatic subjects. Our hypothesis is that airway smooth muscle cell dysfunction plays an important role in the pathogenesis of asthma, and that treatment with inhaled corticosteroids reverses the abnormalities in airway smooth muscle cell function.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Imperial College London
• Collaborator: Royal Brompton & Harefield NHS Foundation Trust
• Treatments: Budesonide

Criteria

Inclusion Criteria:

• Physician diagnosis of asthma

• Age 18-60

• Intermittent asthma symptoms < once/week

• FEV1>80% of predicted

• Not on inhaled corticosteroid therapy

Exclusion Criteria:

• Previous long-term use of inhaled corticosteroids (within 1 year of entry into study)

• Past history of hypersensitivity to budesonide

• Current smokers, or less than 3 years since quitting smoking

• Less than 4 weeks from an exacerbation

• On steroid-sparing agent or immunosuppressant such as azathioprine, methotrexate and ciclosporin

• Concomitant anti-IgE therapy

• Pregnancy

• Previous bronchoscopy within three months of this study